EP4159204

NOVARTIS AG
Application Number
EP22209104A
Filing Date
Dec 20, 2011
Status
Granted And Under Opposition
Jan 12, 2024
Grant Date
Feb 14, 2024
External Links
Slate, Register

Biblio Summary

The patent EP4159204B1 was granted on Feb 14, 2024 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 4 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BRAND MURRAY FULLER LLPNov 14, 2024ADMISSIBLE
GENERICS (U.K.) LIMITEDNov 14, 2024ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIES, LTD.Nov 13, 2024ADMISSIBLE
HAMM&WITTKOPP PATENTANWALTE PARTMBBNov 11, 2024ADMISSIBLE

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245
EP3272764Method For Affinity ChromatographyFeb 7, 20241